EMA provides drug-naming guide; Novartis withdraws Gleevec app in EU for hypertension;

@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma

 @AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce

> Generic drugmaker Dr. Reddy's Laboratories has launched generic antihistamine desloratadine tablets in the U.S., a bioequivalent generic version of Schering Clarinex Reditabs tablets. Item

> FDA staff said they didn't believe Boehringer Ingelheim's once-daily drug for chronic obstructive pulmonary disease offered significant benefits. Story

> Net income at Procter & Gamble ($PG) more than doubled to $4.06 billion in the last quarter. Story

> Bank of America Merrill Lynch put German Bayer on its list of top European stocks, citing confidence in its drug pipeline and agriculture unit. Story

> The European Medicines Agency has lined out its thoughts on naming branded drugs in an update of one of its documents. Item

> The FDA today approved Oxytrol for women, the first over-the-counter treatment for overactive bladder in women ages 18 and older. Release

Medical Device News

 @FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev

 @DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce

> ResMed posts 24% income jump in another big quarter. Article

> iRobot spikes on the Street after FDA OK. Story

Biotech News

 @FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce

@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce

> Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data. Article

> What's in a drug name? Hopefully some Xzitement. News

And Finally... Novartis ($NVS) has withdrawn a marketing application to get approval in Europe for its cancer blockbuster Glivec/Gleevec, as a treatment for pulmonary arterial hypertension. Release

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.